Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Phonetic Associations: A Survey of \Interfacing Worldwide People group\ Language Trade Application - 2Cyber Monday 2025: Save over 70% on HBO Max with this Prime Video streaming deal
- 3Audits of Espresso Types: Which Mix Is for You?
- 4New dinosaur tracks in Italy illustrate herds moving in unison
- 5Over 60 local leaders push Netanyahu to halt haredi draft bill, warn of social rift
- Find Successful Magnificence Items for Sparkling Skin
- 'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale.
- Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
- Heat Wave Fuels Massive Wildfire In Australia
- Cocoa Prices Sink on Favorable Crop Conditions in West Africa
- Step by step instructions to Explore the Close to home Consequence of Cellular breakdown in the lungs
- Beating Wellbeing Difficulties: Individual Victories in Health
- Figure out How to Remain Persuaded During Your Internet based Degree Program
- I work with companies to confront addiction in the workplace. The hidden crisis is costing corporate America millions.
